BMN 290 / BioMarin - LARVOL DELTA

BioMarin announces first quarter 2019 financial results (Biomarin Press Release) - "The Company is currently conducting additional pre-clinical work on BMN 290 and will decide in the first half of 2019 whether to file an IND based on the outcome of those data."

IND • Preclinical

BioMarin announces full year and fourth quarter 2018 results (PRNewswire) - "BMN 290 is a selective chromatin modulation therapy intended for the treatment of Friedreich's ataxia...The Company is currently conducting additional pre-clinical work on BMN 290 and will decide in the first half of 2019 whether to file an IND based on the outcome of those data."

IND • Preclinical